What is it about?

We created a system that uses a DNA molecule that is able to recognize one and only one molecule, and when this molecule is present in our sample it emits visible light. The system works on plasma or whole blood. We used as proof of concept the protein thrombin, but if the adequate sequence of DNA is used the system can be used to recognize any type of molecule. For the system to work only a couple of milliliters of sample are needed and we were able to detect concentrations of thrombin as low as 0.1 micromolar. We named our assay Chimeric aptafluorescence assay CAFA.

Featured Image

Why is it important?

It is important because many assays for clinical diagnostic or research purposes use antibodies and equipment, or ready-made kits that are expensive for certain clinical settings where a more robust technology may be needed. We propose an assay that can give origin to a robust method, that uses simpler equipment to detect molecules useful for clinical diagnostics or in situ detection for research, or commercial purposes.

Perspectives

The use of aptamers is already taking off and are very promising molecules that can be used on a variety of applications. Nevertheless, a point of care application calls​ my attention because most diagnostic tools are designed to be performed in the clinical laboratory and the results will be reported hours later. Nevertheless, now there is the technology to be able to speed up these results and simplify the assays to be able to be performed anywhere anytime. The purpose of the CAFA assay is to contribute to the future development of powerful detection methods to be used in any setting without the need of sending samples to a lab.

Miguel Mendez
Universidad San Francisco de Quito

Read the Original

This page is a summary of: Protein detection in blood via a chimeric aptafluorescence assay: toward point-of-care diagnostic devices, Journal of Biomedical Optics, September 2018, SPIE,
DOI: 10.1117/1.jbo.23.9.097003.
You can read the full text:

Read

Contributors

The following have contributed to this page